Lv1
8 积分 2025-09-11 加入
Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson’s disease
2个月前
已完结
Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease
5个月前
已完结
Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1
5个月前
已关闭
FXR-targeted drug discovery: Recent advances and therapeutic perspectives
5个月前
已完结
Dual peroxisome proliferator-activated receptor α/δ agonists: Hope for the treatment of alcohol-associated liver disease?
5个月前
已关闭
Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
5个月前
已完结
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
5个月前
已完结
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
5个月前
已完结
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH
6个月前
已完结
Targeting the regulation of iron homeostasis as a potential therapeutic strategy for nonalcoholic fatty liver disease
6个月前
已完结
皖公网安备34019202002308
